Hubei Jumpcan Pharmaceutical Co., Ltd. (SHA: 600566)

Market Cap	27.54B
Revenue (ttm)	8.92B
Net Income (ttm)	2.78B
Shares Out	921.70M
EPS (ttm)	3.03
PE Ratio	9.87
Forward PE	9.58
Dividend	1.30 (4.33%)
Ex-Dividend Date	Jun 17, 2024

Volume	745,200
Open	29.78
Previous Close	29.72
Day's Range	29.56 - 30.04
52-Week Range	23.85 - 45.18
Beta	0.15
Analysts	n/a
Price Target	n/a
Earnings Date	Oct 23, 2024

About Hubei Jumpcan Pharmaceutical

Hubei Jumpcan Pharmaceutical Co., Ltd. engages in the research, development, manufacturing, and trading of Chinese traditional medicines, western medicines, daily use chemical based Chinese traditional medicines, and Chinese medicine health products in China. The company offers Chinese and western medicines in the areas of pediatrics, gynecology, pneumology, gastroenterology, and geriatrics; oral and skin care products; and anti-fatigue, anti-aging, antioxidant, and immunity-enhancing Chinese medicine health products. It also develops Chinese a...

• Industry: Drug Manufacturers - Specialty & Generic
• Sector: Healthcare
• CEO: Fei Cao
• Employees: 5,230
• Stock Exchange: Shanghai Stock Exchange
• Ticker Symbol: 600566

Financial Performance

In 2023, Hubei Jumpcan Pharmaceutical's revenue was 9.65 billion, an increase of 7.32% compared to the previous year's 9.00 billion. Earnings were 2.82 billion, an increase of 30.04%.